NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.

CONCLUSIONS: These results demonstrate proof-of-mechanism for indenoisoquinoline TOP1 inhibitors supporting their further clinical development. They also highlight the value of the NCI Comparative Oncology Program (https://ccr.cancer.gov/Comparative-Oncology-Program) for evaluating novel therapies in immune-competent pets with cancers.
PMID: 30061364 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - July 30, 2018 Category: Cancer & Oncology Authors: Burton JH, Mazcko CN, LeBlanc AK, Covey JM, Ji JJ, Kinders RJ, Parchment RE, Khanna C, Paoloni M, Lana SE, Weishaar K, London CA, Kisseberth WC, Krick E, Vail DM, Childress MO, Bryan JN, Barber LG, Ehrhart EJ, Kent MS, Fan TM, Kow KY, Northup N, Wilson-Ro Tags: Clin Cancer Res Source Type: research